PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00139750
- Locations
- π―π΅
Pfizer Investigational Site, Ohita, Japan
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00138723
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3800
- Registration Number
- NCT00138762
- Locations
- π¬π§
Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
Phase 2
Completed
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT00138749
- Locations
- π¨π¦
Pfizer Investigational Site, Pointe-Claire, Quebec, Canada
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
Phase 3
Terminated
- Conditions
- Diabetes MellitusChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT00138671
- Locations
- π©πͺ
Pfizer Investigational Site, Neuss, Germany
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00139061
- Locations
- π«π·
Pfizer Investigational Site, Tierce, France
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 93
- Registration Number
- NCT00137436
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
Zithromax EV in Community-Acquired Pneumonia (CAP)
Phase 4
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00137007
Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Phase 1
Completed
- Conditions
- Fungal Infection
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00136968
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT00137462
- Locations
- π¨π¦
Pfizer Investigational Site, St. Georges de Beauce, Quebec, Canada
Β© Copyright 2025. All Rights Reserved by MedPath